



ASX ANNOUNCEMENT

11 APRIL 2023

## **CAR T Cell Therapies Educational Webinar**

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical stage cell therapy company and an Australian leader in cell therapy, is pleased to announce it will host an educational webinar on CAR T cell therapies for shareholders and interested parties.

Chimeric’s CEO and Managing Director Jennifer Chow and Chief Medical Officer Dr Jason B. Litten will provide an overview on CAR T cell therapy, the background and development of CHM 1101 and a corporate update on Chimeric’s other programs. An opportunity to ask questions will also be provided.

### **CAR T Cell Therapies Educational Webinar: Where are we today and where are we going?**

When: 11am AEST, Tuesday 18 April 2023

Register at: [https://us02web.zoom.us/webinar/register/WN\\_Aj5N5a1YSt2Dz3Gs56EGew](https://us02web.zoom.us/webinar/register/WN_Aj5N5a1YSt2Dz3Gs56EGew)

Upon registering, attendees will receive an email containing information about joining the webinar. A recording will be available at the above link soon after the conclusion of the live session, with the replay to also be made available via Chimeric’s website and social media channels.

Questions can be sent in advance of the webinar to [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

---

### **ABOUT CHIMERIC THERAPEUTICS**

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in



recurrent / progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumors in 7 types of cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in gastrointestinal and neuroendocrine tumours.

CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

## **CONTACT**

### Investors

Jennifer Chow  
Chief Executive Officer and Managing Director  
Chimeric Therapeutics  
T: + 1 9087238387  
E: [jchow@chimerictherapeutics.com](mailto:jchow@chimerictherapeutics.com)  
W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

Paul Hopper  
Executive Chairman  
Chimeric Therapeutics  
T: + 61 406 671 515  
E: [paulhopper@lifescienceportfolio.com](mailto:paulhopper@lifescienceportfolio.com)

### Media

Matthew Wright  
NWR Communications  
P: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)